PE20160124A1 - Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr - Google Patents

Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr

Info

Publication number
PE20160124A1
PE20160124A1 PE2016000013A PE2016000013A PE20160124A1 PE 20160124 A1 PE20160124 A1 PE 20160124A1 PE 2016000013 A PE2016000013 A PE 2016000013A PE 2016000013 A PE2016000013 A PE 2016000013A PE 20160124 A1 PE20160124 A1 PE 20160124A1
Authority
PE
Peru
Prior art keywords
dichloropyridin
indazol
vinyl
ethanol
compound
Prior art date
Application number
PE2016000013A
Other languages
English (en)
Inventor
Daohong Chen
Genshi Zhao
Hong-Yu Li
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20160124A1 publication Critical patent/PE20160124A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona compuestos, caracterizado porque es (E)-2-4(4-(2(5-(1-(3,5-dicloropiridin-4-il) etoxi)-1H-indazol-3-il) vinil)-1H-pirazol-1-il) etanol, o el compuesto (I), o una sal del mismo farmaceuticamente aceptable, util en el tratamiento de cancer
PE2016000013A 2009-05-07 2010-05-04 Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr PE20160124A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
PE20160124A1 true PE20160124A1 (es) 2016-02-24

Family

ID=42238704

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001877A PE20120812A1 (es) 2009-05-07 2010-05-04 Compuestos vinil indazolilo
PE2016000013A PE20160124A1 (es) 2009-05-07 2010-05-04 Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001877A PE20120812A1 (es) 2009-05-07 2010-05-04 Compuestos vinil indazolilo

Country Status (35)

Country Link
US (1) US8268869B2 (es)
EP (1) EP2427449B1 (es)
JP (1) JP5555314B2 (es)
KR (1) KR101373910B1 (es)
CN (1) CN102421769B (es)
AR (1) AR078411A1 (es)
AU (1) AU2010246114B2 (es)
BR (1) BRPI1013748A2 (es)
CA (1) CA2760535C (es)
CL (1) CL2011002781A1 (es)
CO (1) CO6450624A2 (es)
CR (1) CR20110580A (es)
DK (1) DK2427449T3 (es)
EA (1) EA018149B1 (es)
EC (1) ECSP11011441A (es)
ES (1) ES2408117T3 (es)
HK (1) HK1163665A1 (es)
HN (1) HN2011002809A (es)
HR (1) HRP20130323T1 (es)
IL (1) IL216004A (es)
JO (1) JO2860B1 (es)
MA (1) MA33244B1 (es)
ME (1) ME01462B (es)
MX (1) MX2011011342A (es)
MY (1) MY160390A (es)
NZ (1) NZ595553A (es)
PE (2) PE20120812A1 (es)
PL (1) PL2427449T3 (es)
PT (1) PT2427449E (es)
RS (1) RS52795B (es)
SG (1) SG175909A1 (es)
SI (1) SI2427449T1 (es)
TW (1) TWI382982B (es)
UA (1) UA104756C2 (es)
WO (1) WO2010129509A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CA2865388C (en) 2012-03-08 2022-01-04 Astellas Pharma Inc. Novel fgfr3 fusion
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
CN107922349B (zh) * 2015-08-07 2021-05-07 哈尔滨珍宝制药有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
JP6549311B2 (ja) 2015-08-20 2019-07-24 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． インドール誘導体、その調製方法および医薬におけるその使用
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4056558A4 (en) * 2019-11-06 2023-12-27 Jinan University INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND ITS APPLICATIONS
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
JP2023536603A (ja) * 2020-08-11 2023-08-28 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド Ｆｇｆｒ阻害剤化合物及びその使用
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
SG174632A1 (en) 2000-09-11 2011-10-28 Novartis Vaccines & Diagnostic Quinolinone derivatives
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
EP1510516A4 (en) * 2002-05-31 2005-11-02 Eisai Co Ltd PYRAZOL COMPOUND AND MEDICAL COMPOSITION CONTAINING THEM
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
CA2568050A1 (en) 2004-05-26 2005-12-08 Pfizer, Inc. Indazole and indolone derivatives and their use as pharmaceuticals
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
PL2120932T3 (pl) 2006-12-20 2015-02-27 Nerviano Medical Sciences Srl Indazolowe pochodne jako inhibitory kinazy do leczenia raka
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008153858A1 (en) 2007-06-05 2008-12-18 Schering Corporation Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬

Also Published As

Publication number Publication date
CN102421769A (zh) 2012-04-18
JP2012526126A (ja) 2012-10-25
WO2010129509A1 (en) 2010-11-11
IL216004A (en) 2014-01-30
DK2427449T3 (da) 2013-04-22
ES2408117T3 (es) 2013-06-18
CA2760535C (en) 2014-01-14
HRP20130323T1 (en) 2013-05-31
UA104756C2 (uk) 2014-03-11
AU2010246114B2 (en) 2012-12-06
RS52795B (en) 2013-10-31
TW201105652A (en) 2011-02-16
BRPI1013748A2 (pt) 2016-04-05
US20100286209A1 (en) 2010-11-11
CN102421769B (zh) 2014-04-02
AR078411A1 (es) 2011-11-09
HK1163665A1 (en) 2012-09-14
SI2427449T1 (sl) 2013-05-31
NZ595553A (en) 2013-05-31
EP2427449B1 (en) 2013-04-03
JO2860B1 (en) 2015-03-15
SG175909A1 (en) 2011-12-29
ECSP11011441A (es) 2011-12-30
EA018149B1 (ru) 2013-05-30
KR101373910B1 (ko) 2014-03-12
AU2010246114A1 (en) 2011-11-03
MA33244B1 (fr) 2012-05-02
TWI382982B (zh) 2013-01-21
MY160390A (en) 2017-03-15
MX2011011342A (es) 2011-11-18
CO6450624A2 (es) 2012-05-31
ME01462B (me) 2014-04-20
PL2427449T3 (pl) 2013-08-30
US8268869B2 (en) 2012-09-18
EP2427449A1 (en) 2012-03-14
EA201171367A1 (ru) 2012-04-30
HN2011002809A (es) 2013-07-22
IL216004A0 (en) 2012-01-31
KR20120004511A (ko) 2012-01-12
CL2011002781A1 (es) 2012-05-25
JP5555314B2 (ja) 2014-07-23
CA2760535A1 (en) 2010-11-11
PE20120812A1 (es) 2012-07-08
PT2427449E (pt) 2013-05-06
CR20110580A (es) 2012-01-06

Similar Documents

Publication Publication Date Title
PE20160124A1 (es) Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr
DOP2013000072A (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
CR20110684A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
ZA201100026B (en) 4-(pyridin-4-yl)-1h-(1,3,5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
PE20190343A1 (es) Combinaciones de compuestos activos
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
NZ594163A (en) Pyranose derivatives of pestcidal 1,2,4-triazoles
UY31811A (es) Azoles sustituidos como fungicidas
CL2009000923A1 (es) Compuestos derivados de 1-(aminoacetil)-n-(1-cicloalquil)pirrolidina-2-carboxamida sustituidas; composicion farmaceutica; utiles para tratar la hepatitis c.
MX346186B (es) Inhibidores de proteina cinasas.
NZ599513A (en) Compounds for the treatment of dyslipidemia and related diseases
CU24020B1 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
ECSP088781A (es) Derivados de benzimidazol
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
NZ611169A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
TH115254B (th) สารประกอบไวนิลอินดาโซลอิล
TN2013000142A1 (en) Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
TH132151A (th) ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก
CY1117146T1 (el) Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr
ECSP099383A (es) Derivado piperidínico utilizado para tratar enfermedades mediadas por el receptor 5 de quimiocina

Legal Events

Date Code Title Description
FD Application declared void or lapsed